Research and consulting firm GlobalData has released a new report, PharmaPoint: Chronic Heart Failure - Global Drug Forecast and Market Analysis to 2022 and forecasts global sales of Novartis' combination drug LCZ-696 to reach a massive $1.86 billion by 2022.
http://www.drugs.com/clinical_trials/globaldata-upcoming-novartis-chronic-heart-failure-expected-dominate-market-2022-15824.html?
http://www.drugs.com/clinical_trials/globaldata-upcoming-novartis-chronic-heart-failure-expected-dominate-market-2022-15824.html?
No comments:
Post a Comment